Investigating the effect of natural glucoside product on glycemia of patients with type 2 diabetes, lipidemia and fatty liver disease.
Phase 2
Recruiting
- Conditions
- R73.9E78.5Condition 1: Hyperglycemia. Condition 2: Hyperlipidemia.Hyperglycemia, unspecifiedHyperlipidemia, unspecified
- Registration Number
- IRCT20231030059908N4
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Hyperglycemia
Hyperlipidemia
Exclusion Criteria
History of allergy to drug compounds
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie natural glucoside's impact on hyperglycemia and fatty liver disease in type 2 diabetes patients?
How does the natural glucoside product compare to metformin and statins in managing glycemic control and lipid profiles in IRCT20231030059908N4?
What biomarkers could predict response to natural glucoside therapy in patients with concurrent hyperlipidemia and non-alcoholic fatty liver disease?
Are there documented adverse events associated with natural glucoside supplementation in metabolic syndrome populations?
What combination therapies involving natural glucosides show promise for treating insulin resistance and hepatic steatosis in phase II trials?